Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Alterome Therapeutics, Inc.
K36 Therapeutics, Inc.
Atavistik Bio, Inc
Elevation Oncology
Plus Therapeutics
Engeneic Pty Limited
Advanced Accelerator Applications
Revolution Medicines, Inc.
Endocyte
Poseida Therapeutics, Inc.
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Advaxis, Inc.
Aragon Pharmaceuticals, Inc.
Sumitomo Pharma America, Inc.
Blueprint Medicines Corporation
Revolution Medicines, Inc.
Syndax Pharmaceuticals
Bristol-Myers Squibb
AVEO Pharmaceuticals, Inc.
Pharmacyclics LLC.